nodes	percent_of_prediction	percent_of_DWPC	metapath
Nitazoxanide—Urine color abnormal—Mitoxantrone—lymphatic system cancer	0.0458	0.0458	CcSEcCtD
Nitazoxanide—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0319	0.0319	CcSEcCtD
Nitazoxanide—Chromaturia—Mitoxantrone—lymphatic system cancer	0.0302	0.0302	CcSEcCtD
Nitazoxanide—Leukocytosis—Carmustine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Nitazoxanide—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Nitazoxanide—Dysuria—Fludarabine—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Nitazoxanide—Infection—Mechlorethamine—lymphatic system cancer	0.00992	0.00992	CcSEcCtD
Nitazoxanide—Epistaxis—Fludarabine—lymphatic system cancer	0.00957	0.00957	CcSEcCtD
Nitazoxanide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00952	0.00952	CcSEcCtD
Nitazoxanide—Chills—Teniposide—lymphatic system cancer	0.0093	0.0093	CcSEcCtD
Nitazoxanide—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00907	0.00907	CcSEcCtD
Nitazoxanide—Pharyngitis—Fludarabine—lymphatic system cancer	0.00904	0.00904	CcSEcCtD
Nitazoxanide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00868	0.00868	CcSEcCtD
Nitazoxanide—Anaemia—Teniposide—lymphatic system cancer	0.00834	0.00834	CcSEcCtD
Nitazoxanide—Chills—Fludarabine—lymphatic system cancer	0.00817	0.00817	CcSEcCtD
Nitazoxanide—Hypertension—Teniposide—lymphatic system cancer	0.00779	0.00779	CcSEcCtD
Nitazoxanide—Lung disorder—Methotrexate—lymphatic system cancer	0.0076	0.0076	CcSEcCtD
Nitazoxanide—Oedema—Teniposide—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Nitazoxanide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Nitazoxanide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Nitazoxanide—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00734	0.00734	CcSEcCtD
Nitazoxanide—Anaemia—Fludarabine—lymphatic system cancer	0.00733	0.00733	CcSEcCtD
Nitazoxanide—Infection—Teniposide—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Nitazoxanide—Tachycardia—Teniposide—lymphatic system cancer	0.00719	0.00719	CcSEcCtD
Nitazoxanide—Malaise—Fludarabine—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Nitazoxanide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Nitazoxanide—Anorexia—Teniposide—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Nitazoxanide—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00691	0.00691	CcSEcCtD
Nitazoxanide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00684	0.00684	CcSEcCtD
Nitazoxanide—Myalgia—Fludarabine—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Nitazoxanide—Discomfort—Fludarabine—lymphatic system cancer	0.00667	0.00667	CcSEcCtD
Nitazoxanide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Nitazoxanide—Dysuria—Vincristine—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Nitazoxanide—Oedema—Fludarabine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Nitazoxanide—Infection—Fludarabine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Nitazoxanide—Decreased appetite—Teniposide—lymphatic system cancer	0.0064	0.0064	CcSEcCtD
Nitazoxanide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Nitazoxanide—Rash—Mechlorethamine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Nitazoxanide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00629	0.00629	CcSEcCtD
Nitazoxanide—Anorexia—Fludarabine—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Nitazoxanide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Nitazoxanide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00602	0.00602	CcSEcCtD
Nitazoxanide—Chills—Bleomycin—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Nitazoxanide—Nausea—Mechlorethamine—lymphatic system cancer	0.00593	0.00593	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Nitazoxanide—Body temperature increased—Teniposide—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Nitazoxanide—Abdominal pain—Teniposide—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Nitazoxanide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.0058	0.0058	CcSEcCtD
Nitazoxanide—Dyspepsia—Fludarabine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Nitazoxanide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00563	0.00563	CcSEcCtD
Nitazoxanide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Nitazoxanide—Constipation—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Nitazoxanide—Pain—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Nitazoxanide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Nitazoxanide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Nitazoxanide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.0054	0.0054	CcSEcCtD
Nitazoxanide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Nitazoxanide—Anaemia—Bleomycin—lymphatic system cancer	0.00537	0.00537	CcSEcCtD
Nitazoxanide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Nitazoxanide—Asthenia—Teniposide—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Nitazoxanide—Malaise—Bleomycin—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Nitazoxanide—Pruritus—Teniposide—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Nitazoxanide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Nitazoxanide—Diarrhoea—Teniposide—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Nitazoxanide—Myalgia—Bleomycin—lymphatic system cancer	0.00495	0.00495	CcSEcCtD
Nitazoxanide—Back pain—Carmustine—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Nitazoxanide—Discomfort—Bleomycin—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Nitazoxanide—Chills—Mitoxantrone—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Nitazoxanide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Nitazoxanide—Tremor—Carmustine—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Nitazoxanide—Oedema—Bleomycin—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Nitazoxanide—Infection—Bleomycin—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Nitazoxanide—Anaemia—Carmustine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Nitazoxanide—Back pain—Vincristine—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Nitazoxanide—Vomiting—Teniposide—lymphatic system cancer	0.00468	0.00468	CcSEcCtD
Nitazoxanide—Asthenia—Fludarabine—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nitazoxanide—Rash—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nitazoxanide—Dermatitis—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Nitazoxanide—Headache—Teniposide—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Nitazoxanide—Pruritus—Fludarabine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Nitazoxanide—Back pain—Mitoxantrone—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Nitazoxanide—Anorexia—Bleomycin—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Nitazoxanide—Anaemia—Vincristine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Nitazoxanide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Nitazoxanide—Hypertension—Carmustine—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Nitazoxanide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Nitazoxanide—Nausea—Teniposide—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Nitazoxanide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Nitazoxanide—Myalgia—Carmustine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Nitazoxanide—Malaise—Mitoxantrone—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Nitazoxanide—Hypertension—Vincristine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Nitazoxanide—Oedema—Carmustine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Nitazoxanide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Nitazoxanide—Myalgia—Vincristine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Nitazoxanide—Infection—Carmustine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Nitazoxanide—Vomiting—Fludarabine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Nitazoxanide—Rash—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Nitazoxanide—Dermatitis—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Nitazoxanide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Nitazoxanide—Pain—Bleomycin—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Nitazoxanide—Headache—Fludarabine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Nitazoxanide—Tachycardia—Carmustine—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Nitazoxanide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Nitazoxanide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Nitazoxanide—Oedema—Vincristine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Nitazoxanide—Anorexia—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Nitazoxanide—Infection—Vincristine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Nitazoxanide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Nitazoxanide—Oedema—Mitoxantrone—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Nitazoxanide—Nausea—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Nitazoxanide—Infection—Mitoxantrone—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Nitazoxanide—Shock—Mitoxantrone—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Nitazoxanide—Anorexia—Vincristine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Nitazoxanide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Nitazoxanide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Nitazoxanide—Insomnia—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Nitazoxanide—Somnolence—Carmustine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Nitazoxanide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Nitazoxanide—Decreased appetite—Carmustine—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Nitazoxanide—Insomnia—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Nitazoxanide—Pain—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Nitazoxanide—Constipation—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Nitazoxanide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Nitazoxanide—Decreased appetite—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Nitazoxanide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Nitazoxanide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Nitazoxanide—Asthenia—Bleomycin—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Nitazoxanide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nitazoxanide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Nitazoxanide—Constipation—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Nitazoxanide—Pain—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Nitazoxanide—Pruritus—Bleomycin—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Nitazoxanide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Nitazoxanide—Pain—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Nitazoxanide—Constipation—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Nitazoxanide—Body temperature increased—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Nitazoxanide—Abdominal pain—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Nitazoxanide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Nitazoxanide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Nitazoxanide—Dysuria—Methotrexate—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Nitazoxanide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Nitazoxanide—Abdominal pain—Vincristine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Nitazoxanide—Body temperature increased—Vincristine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Nitazoxanide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Nitazoxanide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Nitazoxanide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Nitazoxanide—Vomiting—Bleomycin—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Nitazoxanide—Rash—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Nitazoxanide—Dermatitis—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Nitazoxanide—Asthenia—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Nitazoxanide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Nitazoxanide—Epistaxis—Methotrexate—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Nitazoxanide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Nitazoxanide—Asthenia—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Nitazoxanide—Diarrhoea—Carmustine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Nitazoxanide—Nausea—Bleomycin—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Nitazoxanide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Nitazoxanide—Dizziness—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Nitazoxanide—Diarrhoea—Vincristine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Nitazoxanide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Nitazoxanide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Nitazoxanide—Vomiting—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Nitazoxanide—Dizziness—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Nitazoxanide—Rash—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nitazoxanide—Dermatitis—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nitazoxanide—Headache—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Nitazoxanide—Vomiting—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Nitazoxanide—Rash—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Nitazoxanide—Dermatitis—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Nitazoxanide—Headache—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Nitazoxanide—Nausea—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Nitazoxanide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Nitazoxanide—Rash—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Nitazoxanide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Nitazoxanide—Chills—Methotrexate—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Nitazoxanide—Headache—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Nitazoxanide—Nausea—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Nitazoxanide—Nausea—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Nitazoxanide—Back pain—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Nitazoxanide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Nitazoxanide—Anaemia—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Nitazoxanide—Malaise—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Nitazoxanide—Myalgia—Methotrexate—lymphatic system cancer	0.002	0.002	CcSEcCtD
Nitazoxanide—Discomfort—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Nitazoxanide—Infection—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Nitazoxanide—Anorexia—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Nitazoxanide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Nitazoxanide—Insomnia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Nitazoxanide—Somnolence—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Nitazoxanide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Nitazoxanide—Decreased appetite—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Nitazoxanide—Pain—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Nitazoxanide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Nitazoxanide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Nitazoxanide—Abdominal pain—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Nitazoxanide—Body temperature increased—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Nitazoxanide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Nitazoxanide—Asthenia—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Nitazoxanide—Pruritus—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Nitazoxanide—Diarrhoea—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Nitazoxanide—Dizziness—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Nitazoxanide—Vomiting—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Nitazoxanide—Rash—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Nitazoxanide—Dermatitis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Nitazoxanide—Headache—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Nitazoxanide—Nausea—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
